Secondary bacterial infection in COVID-19 patients is a stronger predictor for death compared to influenza patients.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
16 06 2021
Historique:
received: 07 04 2021
accepted: 01 06 2021
entrez: 17 6 2021
pubmed: 18 6 2021
medline: 8 7 2021
Statut: epublish

Résumé

Secondary bacterial infections are a potentially fatal complication of influenza infection. We aimed to define the impact of secondary bacterial infections on the clinical course and mortality in coronavirus disease 2019 (COVID-19) patients by comparison with influenza patients. COVID-19 (n = 642) and influenza (n = 742) patients, admitted to a large tertiary center in Israel and for whom blood or sputum culture had been taken were selected for this study. Bacterial culture results, clinical parameters, and death rates were compared. COVID-19 patients had higher rates of bacterial infections than influenza patients (12.6% vs. 8.7%). Notably, the time from admission to bacterial growth was longer in COVID-19 compared to influenza patients (4 (1-8) vs. 1 (1-3) days). Late infections (> 48 h after admission) with gram-positive bacteria were more common in COVID-19 patients (28% vs. 9.5%). Secondary infection was associated with a higher risk of death in both patient groups 2.7-fold (1.22-5.83) for COVID-19, and 3.09-fold (1.11-7.38) for Influenza). The association with death remained significant upon adjustment to age and clinical parameters in COVID-19 but not in influenza infection. Secondary bacterial infection is a notable complication associated with worse outcomes in COVID-19 than influenza patients. Careful surveillance and prompt antibiotic treatment may benefit selected patients.

Identifiants

pubmed: 34135459
doi: 10.1038/s41598-021-92220-0
pii: 10.1038/s41598-021-92220-0
pmc: PMC8209102
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

12703

Références

Microbes Infect. 2020 Oct;22(9):481-488
pubmed: 32561409
Lancet Respir Med. 2021 Mar;9(3):251-259
pubmed: 33341155
Am J Med. 2006 Jun;119(6 Suppl 1):S11-9; discussion S62-70
pubmed: 16735146
Nat Rev Microbiol. 2014 Apr;12(4):252-62
pubmed: 24590244
Front Microbiol. 2017 Jun 23;8:1041
pubmed: 28690590
Antimicrob Agents Chemother. 2005 Apr;49(4):1306-11
pubmed: 15793102
J Infect. 2012 Sep;65(3):223-30
pubmed: 22543245
Clin Infect Dis. 2020 Dec 3;71(9):2459-2468
pubmed: 32358954
J Immunol. 2013 Sep 1;191(5):2047-52
pubmed: 23964104
J Infect. 2009 Sep;59 Suppl 1:S4-16
pubmed: 19766888
J Infect Dis. 2008 Oct 1;198(7):962-70
pubmed: 18710327
Front Immunol. 2020 Feb 13;11:117
pubmed: 32117268
mBio. 2016 Dec 13;7(6):
pubmed: 27965455
J Infect. 2020 Aug;81(2):266-275
pubmed: 32473235
PLoS One. 2020 Nov 23;15(11):e0242533
pubmed: 33226995

Auteurs

Noa Shafran (N)

Department of Medicine D, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel.

Inbal Shafran (I)

Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.

Haim Ben-Zvi (H)

Microbiology Laboratory, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel.

Summer Sofer (S)

Department of Clinical Microbiology and Immunology, The Sackler Faculty of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel.

Liron Sheena (L)

Department of Medicine F, Rabin Medicine, Tel Aviv University, Tel Aviv, Israel.

Ilan Krause (I)

Department of Medicine F, Rabin Medicine, Tel Aviv University, Tel Aviv, Israel.
The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Amir Shlomai (A)

Department of Medicine D, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel.
The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Elad Goldberg (E)

Department of Medicine F, Rabin Medicine, Tel Aviv University, Tel Aviv, Israel.
The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Ella H Sklan (EH)

Department of Clinical Microbiology and Immunology, The Sackler Faculty of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel. sklan@tauex.tau.ac.il.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH